The specifics, since they change the answer: a 29G needle · 6.67 mg/mL.
I would rather understand the derivation than memorise the outcome.
Two people I asked gave two answers that differ by a factor of ten, which is suggestive.
What is the general form of this calculation?
At 6.67 mg/mL every microlitre left behind is 6.67 µg, so a 50 µL hub costs 0.334 mg per draw and a 5 µL fixed-needle barrel costs 0.0333 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 3.33 mg gone, which at 6.67 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 16.7 per cent; against a 0.25 mg dose it is 133.4 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 29G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
The short answer is that dead space is small in absolute terms and huge as a fraction of a small dose, which is why it feels like a rounding error and behaves like a systematic loss.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
| Appearance | Interpretation | Action |
|---|---|---|
| Intact opaque puck, proud of base | Cycle ran correctly | Proceed |
| Slumped to one side | Shipped before fully dry, or vibration | Usually usable; note it |
| Glassy translucent film | Collapse above glass transition | Test before use |
| Melt-back ring at stopper | Thermal excursion in transit | Test before use |
| No visible cake at all | Very low fill, or nothing there | Weigh it; query the supplier |
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
If cost matters, this is the first thing to change, not the last.
edited 24 Jul 2026 by tenth_of_a_unit — added a caveat about sampling
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsStart from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.
Configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.
Specifically, delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
The switch nearly doubles your vial, which is better than most other optimisations combined.
edited 30 Jul 2026 by v_ramaswamy — corrected a unit error in the worked example
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.